SU11274影响食管癌Eca109细胞生物学行为的时辰效应探讨
|
摘要
目的：本文旨在研究c-Met抑制剂SU11274对食管癌Eca109细胞株生物学行为的影响,并通过其作用靶点c-Met蛋白和C-met mRNA与生物钟基因Clock mRNA的可能潜在联系,进一步探讨在其作用过程中是否有时辰效应的存在。
方法：(1)体外培养食管癌Eca109细胞株,用免疫细胞化学检测c-Met蛋白的表达。(2)用SU11274(IC50为20nM)处理Eca109细胞,通过MTT生长曲线、划痕实验、transwell侵袭小室以及FCM,观察药物对细胞生长、迁移、侵袭能力以及凋亡率与细胞周期的影响。(3)体外培养食管癌Eca109细胞株,用RT-PCR法分别检测不同时间点Clock与C-met mRNA的表达。(4)用流式细胞仪检测各时间点c-Met蛋白的表达。(5)不同时间点SU11274处理细胞24h后,用流式细胞仪检测细胞周期。
结果：(1)Eca109细胞表达c-Met蛋白。(2)SU11274实验组细胞生长,迁移和浸润能力低于对照组,凋亡率高于对照组,增殖指数低于对照组。(3)48h内Clock基因表达呈节律性波动(P<0.05)。(4)24h内Clock与C-met基因表达呈相似节律性波动(P<0.01),。(5)24h内c-Met蛋白表达呈节律性波动(P<0.05),出现表达高峰的时间点与C-met mRNA表达高峰时间点一致。(6)不同时间点SU11274处理细胞后,细胞增殖指数抑制率不同(P<0.01)。
结论：(1)c-Met抑制剂SU11274可以抑制Eca109细胞的生长和增殖,减弱迁移和浸润能力,增加细胞凋亡。(2)证实体外培养的食管癌Eca109细胞Clock的表达随时间变化存在节律性。(3)首次发现食管癌Eca109细胞C-met mRNA与c-Met蛋白在24小时内的表达呈节律性波动。(4)在不同时间点经SU11274处理后,细胞增殖指数抑制率不同,提示提示在食管癌靶向治疗中要考虑时辰效应。
Objective:To study the impact of SU11274-c-Met protein inhibitor on the biological behavior of Eca109 cells, and via the potential relationships between its target-c-Met protein, c-met mRNA and clock mRNA to explore whether time effect exists during the treatment by SU11274 on Eca109 cells.
Method:(1) Eca109 cells were cultured in vitro and c-Met protein was tested by immuncytochemistry. (2) Cell proliferation, movement, invasion, apoptosis rate and cell cycle were detected with MTT, cell scratch healing test, transwell assay and FCM after treated with SU11274 (20nM was used as the IC5o). (3) Clock and C-met mRNAs were assayed by RT-PCR. (4) The expression of c-Met protein at different time was detected by FCM. (5) The cell cycles after treated with SU11274 at different time points were detected by FCM.
Result:(1) Eca109 cell expressed c-Met protein. (2) After the cells were treated with SU11274, the abilities of growth, migration and invasion were decreased contrast with those in control groups, and the apoptosis rates were higher than that in control groups, while the percentages of cells at S stage in DNA duplication were less. (3) RT-PCR results showed that expression of Clock mRNA was oscillating during 48h (P＜0.05). (4) The Clock and C-met mRNA expressed with circadian rhythms in 24h (P<0.01), and the expression in both of them showed similarity. (5) The c-Met protein expressed with oscillation in 24h (P<0.05) which was in accord with that of C-met mRNA. (6) The decreasing extent of proliferation index was different when Eca109 cells were treated by SU11274 at different time points.
Conclusion:(1) The c-Met inhibitor SU11274 can inhibit Eca109 cells growing, infiltrating and migration, increase cell apoptosis rate and restrain cells transiting to S from Gl stage in cell proliferation cycle. (2) Eca109 cell cultured in vitro express Clock with rhythm. (3) Eca109 cells expressed C-met mRNA and c-Met protein with rhythms. (4) The inhibition rates of proliferation index were different when Eca109 cells were treated at different time points, suggesting that time effect exist in the treatment for esophageal cancer by SU11274 and be taken seriously.
方法：(1)体外培养食管癌Eca109细胞株,用免疫细胞化学检测c-Met蛋白的表达。(2)用SU11274(IC50为20nM)处理Eca109细胞,通过MTT生长曲线、划痕实验、transwell侵袭小室以及FCM,观察药物对细胞生长、迁移、侵袭能力以及凋亡率与细胞周期的影响。(3)体外培养食管癌Eca109细胞株,用RT-PCR法分别检测不同时间点Clock与C-met mRNA的表达。(4)用流式细胞仪检测各时间点c-Met蛋白的表达。(5)不同时间点SU11274处理细胞24h后,用流式细胞仪检测细胞周期。
结果：(1)Eca109细胞表达c-Met蛋白。(2)SU11274实验组细胞生长,迁移和浸润能力低于对照组,凋亡率高于对照组,增殖指数低于对照组。(3)48h内Clock基因表达呈节律性波动(P<0.05)。(4)24h内Clock与C-met基因表达呈相似节律性波动(P<0.01),。(5)24h内c-Met蛋白表达呈节律性波动(P<0.05),出现表达高峰的时间点与C-met mRNA表达高峰时间点一致。(6)不同时间点SU11274处理细胞后,细胞增殖指数抑制率不同(P<0.01)。
结论：(1)c-Met抑制剂SU11274可以抑制Eca109细胞的生长和增殖,减弱迁移和浸润能力,增加细胞凋亡。(2)证实体外培养的食管癌Eca109细胞Clock的表达随时间变化存在节律性。(3)首次发现食管癌Eca109细胞C-met mRNA与c-Met蛋白在24小时内的表达呈节律性波动。(4)在不同时间点经SU11274处理后,细胞增殖指数抑制率不同,提示提示在食管癌靶向治疗中要考虑时辰效应。
Objective:To study the impact of SU11274-c-Met protein inhibitor on the biological behavior of Eca109 cells, and via the potential relationships between its target-c-Met protein, c-met mRNA and clock mRNA to explore whether time effect exists during the treatment by SU11274 on Eca109 cells.
Method:(1) Eca109 cells were cultured in vitro and c-Met protein was tested by immuncytochemistry. (2) Cell proliferation, movement, invasion, apoptosis rate and cell cycle were detected with MTT, cell scratch healing test, transwell assay and FCM after treated with SU11274 (20nM was used as the IC5o). (3) Clock and C-met mRNAs were assayed by RT-PCR. (4) The expression of c-Met protein at different time was detected by FCM. (5) The cell cycles after treated with SU11274 at different time points were detected by FCM.
Result:(1) Eca109 cell expressed c-Met protein. (2) After the cells were treated with SU11274, the abilities of growth, migration and invasion were decreased contrast with those in control groups, and the apoptosis rates were higher than that in control groups, while the percentages of cells at S stage in DNA duplication were less. (3) RT-PCR results showed that expression of Clock mRNA was oscillating during 48h (P＜0.05). (4) The Clock and C-met mRNA expressed with circadian rhythms in 24h (P<0.01), and the expression in both of them showed similarity. (5) The c-Met protein expressed with oscillation in 24h (P<0.05) which was in accord with that of C-met mRNA. (6) The decreasing extent of proliferation index was different when Eca109 cells were treated by SU11274 at different time points.
Conclusion:(1) The c-Met inhibitor SU11274 can inhibit Eca109 cells growing, infiltrating and migration, increase cell apoptosis rate and restrain cells transiting to S from Gl stage in cell proliferation cycle. (2) Eca109 cell cultured in vitro express Clock with rhythm. (3) Eca109 cells expressed C-met mRNA and c-Met protein with rhythms. (4) The inhibition rates of proliferation index were different when Eca109 cells were treated at different time points, suggesting that time effect exist in the treatment for esophageal cancer by SU11274 and be taken seriously.
引文
[1]郑杰.做好靶向病理诊断夯实靶向治疗的基础[J].中华病理学杂志,2007,36(7)：433～436
[2]Cooper CS, Park M, Blair DG, et al. Molecular cloning of a new transforming gene from a chemically transformed human cell line [J]. Nature,1984,311 (5981): 29-33
[3]Stoker M, Gherardi E, Perryman M, et al. Scatter factor is a fibroblast-derived modulator of epithelial cell mobility [J]. Nature,1987,327 (6119):239-242
[4]Gherardi E. and Stoker M. Hepatocytes and scatter factor [J]. Nature,1990,346 (6281):228
[5]Nakamura T, Nishizava T, Hagiya M, et al. Molecular cloning and expression of human hepatocyte growth factor [J]. Nature,1989,342(6248):440-443
[6]Bottaro DP, Rubin JS, Faletto DL, et al. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product [J].Science,1991,251 (4995): 802-804
[7]Birchmeier C, Birchmeier W, Gherardi E, et al. Met, metastasis, motility and more [J]. Nat Rev Mol Cell Biol,2003,4 (12):915-925
[8]Osada S, Saji S. New approach to cancer therapy:The application of signal transduction to anti-cancer drug [J]. Curr Med Chem Anti-Cancer Agents,2003, 3:119-131
[9]Rosario M, Birchmeier W. How to make tubes:signaling by the Met receptor tyrosine kinase [J]. Trends Cell Biol,2003,13(6):328-335
[10]Zhang YW, Su Y, Volpert OV, et al. Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation [J]. Proc Natl Acad Sci USA,2003,100(22):12718-23
[11]Kapos-Novak P, Lee JS, Gomez-Quimz L, et al. Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype [J]. J Clin Invest,2006,116(6):1582-1595
[12]Pongchairerk U, Guan JL, Leardkamolkam V. Focal adhesion kinase and Src phosphorylations in HGF-induced proliferation and invasion of human cholangiocarcinoma cell line, IIuCCA-l[J]. World J Gastroenterol,2005, 11(37):5845-5852
[13]Bauer TW, Somcio RJ, Fan F, et al. Regulatory role of c-Met in insulin-like growth factor-I receptor mediated migration and invasion of human pancreatic carcinoma cells [J]. Mol Cancer Ther,2006,5(7):1676-1682
[14]Masuya D, Huang C, Liu D, et al. The tumour-stromal interaction between intratumoral c-Met and stromal hepatocyte growth factor associated with tumour growth and prognosis in non-small-cell lung cancer patients [J]. Br J Cancer,2004, 90(8):1555-1562
[15]Wasenius VM, Hemmer S, Karjalainen-Lindsberg ML, et al. MET receptor tyrosine kinase sequence alteration in differentiated thyroid carcinoma [J].Am J Surg Pathol,2005,29(4):544-549
[16]Jagadeeswaran R, Ma PC, Seiwert TY, et al. Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma [J]. Cancer Res,2006,66(1):352-361
[17]Qian CN, Guo X, Cao B, et al. Met protein expression level correlates with survival in patients with late-stage nasopharyngeal carcinoma [J].Cancer Res,2002, 62(1):589-596
[18]董彤, 辛晓燕, 马向东.肝细胞生长因子及其受体c-met在卵巢癌细胞中的表达[J].肿瘤研究与临床,2006,18(8)：541-543
[19]Sandra Sephtona, David Spiegelb. Circadian disruption in cancer:a neuroendocrine-immune pathway from stress to disease? [J].Brain, Behavior, and Immunity,2003,17:321-328
[20]Yang X, WoA PA, Oh EY, et al. Down regulation of circadian clock gene period2 accelerates breast cancer growth by altering its daily growth rhythm [J]. Breast Cancer Res Treat,2009,117(2):423-431
[21]Luis J.Herrera, Talal El-Hefnawy, Pierre E, et al. The HGF Receptor c-Met Is Overexpressed in Esophageal Adenocarcinoma [J].Neoplasia,2005,7(1):75-84
[22]JIANG Yong-quan, BAI Xiao-Ming, CHAI Li-sun, et al. Expression of Ezrin protein and c-met in human esophageal squamous cell carcinoma and their clinical significance [J].Cancer Research and Clinic,2009,21(5):323-325
[23]Katrin Ackermann, Faramarz Dehghani, Roman Bux et al. Day-night expression patterns of clock genes in the human pineal gland [J]. Pineal Res.2007,43:185-194.
[24]Kenessey M, Keszthelyi Z, Kramer J, et al. Inhibition of c-Met with the Specific Small Molecule Tyrosine Kinase Inhibitor SU11274 Decreases Growth and Metastasis Formation of Experimental Human Melanoma [J]. Current Cancer Drug Targets,2010,10(3):332-342
[25]Storch KF, Lipan OLeykin I, et al. Extensive and divergent circadian gene expression in liver and heart. Nature (Lond.),2002,417(6884):78-83
[26]Kita Y, Shiozawa M, Jin W, et al. Implications of circadian gene expression in kidney, liver and the effects of fasting on pharmacogenomic studies [J]. Pharmacogenetics,2002,12(1):55-65
[27]Hurshesky W, Lanin D Huas E. Evidence for an ontogenetic basis for circadian coordination of cancer cell proliferation [J]. Nat Cnacer Inst.1998(19):1480-1484
[28]Fu L, Palicano H, Liu J, et al. The circadian gene Period2 plays an important role in tumor suppression and DNA damage response in vivo [J]. Cell.2002,111(1):41-50
[29]Zhu Y, Brown H, Zhang Y, et al.Period3 structural variation:a circadian biomarker associate with breast cancer in young women [J]. Cancer Epidemiology Biomarker & Prevention.2005,14:218-270
[30]Levi F. Chronopharmacology of anticancer agents In:Redferm PH, Lemmer B (Eds).Handbook of Experimental Pharmacology:physiology and pharmacology of Biological Rhythms [J]. Berlin:Springer-Verlag,1997:299-331
[31]Atsuko Fujioka, Naoyuki Takashima, Yasufumi Shigeyoshi. Circadian rhythm generation in a glioma cell line [J]. Biochemical and Biophysical Research Communications,2006,346:169-174
[32]Sephton SM, Spiegel D. Circadian disruption in cancer:A neuroendocrine-immune pathway from stress to disease [J]. Brain Behav Immu,2003, 17(5):321-328
[33]杨春蕾,彭涛,屈艺, 等.异鼠李素对Eca109细胞DNA的合成和c-Myc基因表达对近日节律的影响[J].生物医学工程学杂志,2005,2(6)：1227-1230
[34]Guo-qing Wang, Yu-Zhen Du,& Jian Tong. Daily oscillation and photoresponses of clock gene, clock, and clock-associated gene, arylalkylamine N-acetyltransferase gene transcriptions in the rat pineal gland. Chronobiology International.2007,24(1): 9-20
[35]杜玉珍,王国卿,焦旸,等.大鼠外周血淋巴细胞钟相关基因的筛选和鉴定.苏州大学学报(医学版).2005,25(6)943-946,997
[36]Levi F. Cancer chronotherapy:principles, applications and perspectives [J].Cancer,2003,97(1):155-169
[37]李光明,刘延友,朱彬,等.鼻咽癌时辰放疗与常规放疗的比较[J].航天医学与医学工程,2006,19(3)：225-227
[1]Cooper CS, Park M, Blair DG, et al. Molecular cloning of a new trans-forming gene from a chemically transformed human cell line [J]. Nature,1984,311 (5981): 29-33
[2]Stoker M, Gherardi E, Perryman M, et al. Scatter factor is a fibroblast-derived modulator of epithelial cell mobility [J]. Nature,1987,327 (6119):239-242
[3]Gherardi E. and Stoker M. Hepatocytes and scatter factor [J]. Nature,1990,346 (6281):228
[4]Bottaro DP, Rubin JS, Faletto DL, et al. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product [J].Science,1991,251 (4995): 802-804
[5]Nakamura T, Nishizava T, Hagiya M, et al. Molecular cloning and expression of human hepatocyte growth factor [J]. Nature,1989,342(6248):440-443
[6]Birchmeier C, Birchmeier W, Gherardi E, et al. Met, metastasis, motility and more [J]. Nat Rev Mol Cell Biol,2003,4 (12):915-925
[7]Rosario M, Birchmeier W. How to make tubes:signaling by the Met receptor tyrosine kinase [J]. Trends Cell Biol,2003,13(6):328-335
[8]Wislez M, Rabbe N, Marchal J, et al. Hepatocyte growth factor production by neutrophils infiltrating bronchioloalveolar subtype pulmonary adenocarcinoma:role in tumor progression and death [J].Cancer Res,2003,63(6):1405-1412
[9]Wang Yuping, Hao Zhiwei, Chu Tianjiao, et al.Expression of HGF and its receptor C-Met in breast cancer tissue [J]. Journal of Zhengzhou University,2005, 40(6):1133-1134. (In Chinese)
[10]Liu Ruijuan. Expression of Hepatocyte Growth Factor and its Receptor c-met in Non-small Cell Lung Carcinoma and Relationship between them [J] Practical Journal of Cancer,2006,21 (5):479-482. (In Chinese)
[11]Yu Shipeng, Guo Huan, Ban Bo, et al. Expression of thyroperoxidase mRNA, HGF/c-Met protein in human thyroid nodule [J].Shandong Chinese Medicine,2008, 48(34):15-17. (In Chinese)
[12]Kapos-Novak P, Lee JS, Gomez-Quimz L, et al. Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype [J]. J Clin Invest,2006,116(6):1582-1595
[13]Pongchairerk U, Guan JL, Leardkamolkam V. Focal adhesion kinase and Src phosphorylations in HGF-induced proliferation and invasion of human cholangiocarcinoma cell line, HuCCA-1 [J]. World J Gastroenterology,2005, 11(37):5845-5852
[14]Bauer TW, Somcio RJ, Fan F, et al.Regulatory role of c-Met in insulin-like growth factor-I receptor-mediated migration and invasion of human pancreatic carcinoma cells [J]. Mol Cancer Ther,2006,5(7):1676-1682
[15]Masuya D, Huang C, Liu D, et al. The tumour-stromal interaction between intratumoral c-Met and stromal hepatocyte growth factor associated with tumour growth and prognosis in non-small-cell lung cancer patients [J]. Br J Cancer,2004, 90(8):1555-1562
[16]Wasenius VM, Hemmer S, Karjalainen-Lindsberg ML, et al. MET receptor tyrosine kinase sequence alteration in differentiated thyroid carcinoma [J]. Am J Surg Pathol,2005,29(4):544-549
[17]Jagadeeswaran R, Ma PC, Seiwert TY, et al. Functional analysis of c-Met/ hepatocyte growth factor pathway in malignant pleural mesothelioma [J]. Cancer Res, 2006,66(1):352-361
[18]Qian CN, Guo X, Cao B, et al. Met protein expression level correlates with survival in patients with late-stage nasopharyngeal carcinoma [J].Cancer Res,2002, 62(1):589-596
[19]Dong Tong, Xin Xiaoyan, Ma Xiangdong. Hepatocyte growth factor and c-met's expression in ovarian tumor cell [J]. Clinical Cancer Research,2006,18(8):541-543 (In Chinese)
[20]Wang Yanfei, Pu Zhangjie, Yin Guangwen, et al. Progress on the relationship between HGF/c-Met system and the Head and Neck Cancer [J]. Practical Chinese Medicine,2008,3(3):135-137
[21]Zhang YW, Su Y, Volpert OV, et al. Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation [J]. Proc Natl Acad Sci USA,2003,100(22):12718-23
[22]Watson GA, Zhang X, Stang MT, et al. Inhibition of c-Met as a therapeutic strategy for esophageal adenocarcinoma. Neoplasia,2006, 11(8):949-955
[23]Wen J, Matsumoto K, Taniura N, et al. Inhibition of colon cancer growth and metastasis by NK4 gene repetitive delivery in mice [J]Biochem Biophys Res Commun,2007,358(1):117-123
[24]Hu Mingtai, Ha Xiaoqin, Gao Peng. The mechanism of Hepatocyte growth factor antagonist NK4 inhibiting the tumor [J]. Journal of Fourth Military Medical University,2008,29(1):86-88. (In Chinese)
[25]Matsumoto K, Nakamura T, Sakai K, et al. Hepatocyte growth factor and Met in tumor biology and therapeutic approach with NK4 [J].Proteomics,2008,8:3360-3370
[26]Raymond WW, Cruz AC, Caughey GH. Mast cell and neutrophil peptidases attack an activation segment in hepatocyte growth factor to generate NK4-like antagonists [J]. J Bilo Chem.2006,1281 (3):1489-1494
[27]Saga Y, Mizukami H, Suzuki M, et al. Expression of HGF/NK4 in ovarian cancer cells suppresses intraperitoneal dissemination and extends host survival [J]. Gene Ther,2001,8(19):1450-5
[28]Christensen JG, Burrow J, Salgia R. C-met as a target for human cancer and characterization of inhibitors for therapeutic intervention [J].Cancer Lett,2005, 225(1):1-26
[29]D avies G, Watkins G, Mason MD, et al. Targeting the HGF/SF receptor c-met using a hammerhead ribozyme transgene reduces in vitro invasion and migration in prostate cancer cells [J]. Prostate,2004,60(4):317-324
[30]Pan Weibing, Zhang Qinghan, Toshikazu Nakamura, et al. IntrAuction of exogenous NK4 gene into bladder transitional epithelial cells can reduce the HGF in tumor cells [J]. Chinese Journal of Experimental Surgery,2007,24(5):576-577. (In Chinese)
[31]Heideman DAM, Overmeer RM, Van Beusechem, et al. Inhibition of angiogenesis and HGF/c-Met-elicited malignant processes in human hepatocellular carcinoma cells using adenoviral vector mediated NK4 gene therapy [J]. Cancer Gene Ther,2005,12(12):954-962
[32]Buhles A, Collins SA, van Pijkerey JP, et al. Anti-metastatic effects of viral and non-viral mediated NK4 delivery to tumours [J]. Genet Vaccines and Ther, 2009,3(7):5
[2]Cooper CS, Park M, Blair DG, et al. Molecular cloning of a new transforming gene from a chemically transformed human cell line [J]. Nature,1984,311 (5981): 29-33
[3]Stoker M, Gherardi E, Perryman M, et al. Scatter factor is a fibroblast-derived modulator of epithelial cell mobility [J]. Nature,1987,327 (6119):239-242
[4]Gherardi E. and Stoker M. Hepatocytes and scatter factor [J]. Nature,1990,346 (6281):228
[5]Nakamura T, Nishizava T, Hagiya M, et al. Molecular cloning and expression of human hepatocyte growth factor [J]. Nature,1989,342(6248):440-443
[6]Bottaro DP, Rubin JS, Faletto DL, et al. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product [J].Science,1991,251 (4995): 802-804
[7]Birchmeier C, Birchmeier W, Gherardi E, et al. Met, metastasis, motility and more [J]. Nat Rev Mol Cell Biol,2003,4 (12):915-925
[8]Osada S, Saji S. New approach to cancer therapy:The application of signal transduction to anti-cancer drug [J]. Curr Med Chem Anti-Cancer Agents,2003, 3:119-131
[9]Rosario M, Birchmeier W. How to make tubes:signaling by the Met receptor tyrosine kinase [J]. Trends Cell Biol,2003,13(6):328-335
[10]Zhang YW, Su Y, Volpert OV, et al. Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation [J]. Proc Natl Acad Sci USA,2003,100(22):12718-23
[11]Kapos-Novak P, Lee JS, Gomez-Quimz L, et al. Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype [J]. J Clin Invest,2006,116(6):1582-1595
[12]Pongchairerk U, Guan JL, Leardkamolkam V. Focal adhesion kinase and Src phosphorylations in HGF-induced proliferation and invasion of human cholangiocarcinoma cell line, IIuCCA-l[J]. World J Gastroenterol,2005, 11(37):5845-5852
[13]Bauer TW, Somcio RJ, Fan F, et al. Regulatory role of c-Met in insulin-like growth factor-I receptor mediated migration and invasion of human pancreatic carcinoma cells [J]. Mol Cancer Ther,2006,5(7):1676-1682
[14]Masuya D, Huang C, Liu D, et al. The tumour-stromal interaction between intratumoral c-Met and stromal hepatocyte growth factor associated with tumour growth and prognosis in non-small-cell lung cancer patients [J]. Br J Cancer,2004, 90(8):1555-1562
[15]Wasenius VM, Hemmer S, Karjalainen-Lindsberg ML, et al. MET receptor tyrosine kinase sequence alteration in differentiated thyroid carcinoma [J].Am J Surg Pathol,2005,29(4):544-549
[16]Jagadeeswaran R, Ma PC, Seiwert TY, et al. Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma [J]. Cancer Res,2006,66(1):352-361
[17]Qian CN, Guo X, Cao B, et al. Met protein expression level correlates with survival in patients with late-stage nasopharyngeal carcinoma [J].Cancer Res,2002, 62(1):589-596
[18]董彤, 辛晓燕, 马向东.肝细胞生长因子及其受体c-met在卵巢癌细胞中的表达[J].肿瘤研究与临床,2006,18(8)：541-543
[19]Sandra Sephtona, David Spiegelb. Circadian disruption in cancer:a neuroendocrine-immune pathway from stress to disease? [J].Brain, Behavior, and Immunity,2003,17:321-328
[20]Yang X, WoA PA, Oh EY, et al. Down regulation of circadian clock gene period2 accelerates breast cancer growth by altering its daily growth rhythm [J]. Breast Cancer Res Treat,2009,117(2):423-431
[21]Luis J.Herrera, Talal El-Hefnawy, Pierre E, et al. The HGF Receptor c-Met Is Overexpressed in Esophageal Adenocarcinoma [J].Neoplasia,2005,7(1):75-84
[22]JIANG Yong-quan, BAI Xiao-Ming, CHAI Li-sun, et al. Expression of Ezrin protein and c-met in human esophageal squamous cell carcinoma and their clinical significance [J].Cancer Research and Clinic,2009,21(5):323-325
[23]Katrin Ackermann, Faramarz Dehghani, Roman Bux et al. Day-night expression patterns of clock genes in the human pineal gland [J]. Pineal Res.2007,43:185-194.
[24]Kenessey M, Keszthelyi Z, Kramer J, et al. Inhibition of c-Met with the Specific Small Molecule Tyrosine Kinase Inhibitor SU11274 Decreases Growth and Metastasis Formation of Experimental Human Melanoma [J]. Current Cancer Drug Targets,2010,10(3):332-342
[25]Storch KF, Lipan OLeykin I, et al. Extensive and divergent circadian gene expression in liver and heart. Nature (Lond.),2002,417(6884):78-83
[26]Kita Y, Shiozawa M, Jin W, et al. Implications of circadian gene expression in kidney, liver and the effects of fasting on pharmacogenomic studies [J]. Pharmacogenetics,2002,12(1):55-65
[27]Hurshesky W, Lanin D Huas E. Evidence for an ontogenetic basis for circadian coordination of cancer cell proliferation [J]. Nat Cnacer Inst.1998(19):1480-1484
[28]Fu L, Palicano H, Liu J, et al. The circadian gene Period2 plays an important role in tumor suppression and DNA damage response in vivo [J]. Cell.2002,111(1):41-50
[29]Zhu Y, Brown H, Zhang Y, et al.Period3 structural variation:a circadian biomarker associate with breast cancer in young women [J]. Cancer Epidemiology Biomarker & Prevention.2005,14:218-270
[30]Levi F. Chronopharmacology of anticancer agents In:Redferm PH, Lemmer B (Eds).Handbook of Experimental Pharmacology:physiology and pharmacology of Biological Rhythms [J]. Berlin:Springer-Verlag,1997:299-331
[31]Atsuko Fujioka, Naoyuki Takashima, Yasufumi Shigeyoshi. Circadian rhythm generation in a glioma cell line [J]. Biochemical and Biophysical Research Communications,2006,346:169-174
[32]Sephton SM, Spiegel D. Circadian disruption in cancer:A neuroendocrine-immune pathway from stress to disease [J]. Brain Behav Immu,2003, 17(5):321-328
[33]杨春蕾,彭涛,屈艺, 等.异鼠李素对Eca109细胞DNA的合成和c-Myc基因表达对近日节律的影响[J].生物医学工程学杂志,2005,2(6)：1227-1230
[34]Guo-qing Wang, Yu-Zhen Du,& Jian Tong. Daily oscillation and photoresponses of clock gene, clock, and clock-associated gene, arylalkylamine N-acetyltransferase gene transcriptions in the rat pineal gland. Chronobiology International.2007,24(1): 9-20
[35]杜玉珍,王国卿,焦旸,等.大鼠外周血淋巴细胞钟相关基因的筛选和鉴定.苏州大学学报(医学版).2005,25(6)943-946,997
[36]Levi F. Cancer chronotherapy:principles, applications and perspectives [J].Cancer,2003,97(1):155-169
[37]李光明,刘延友,朱彬,等.鼻咽癌时辰放疗与常规放疗的比较[J].航天医学与医学工程,2006,19(3)：225-227
[1]Cooper CS, Park M, Blair DG, et al. Molecular cloning of a new trans-forming gene from a chemically transformed human cell line [J]. Nature,1984,311 (5981): 29-33
[2]Stoker M, Gherardi E, Perryman M, et al. Scatter factor is a fibroblast-derived modulator of epithelial cell mobility [J]. Nature,1987,327 (6119):239-242
[3]Gherardi E. and Stoker M. Hepatocytes and scatter factor [J]. Nature,1990,346 (6281):228
[4]Bottaro DP, Rubin JS, Faletto DL, et al. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product [J].Science,1991,251 (4995): 802-804
[5]Nakamura T, Nishizava T, Hagiya M, et al. Molecular cloning and expression of human hepatocyte growth factor [J]. Nature,1989,342(6248):440-443
[6]Birchmeier C, Birchmeier W, Gherardi E, et al. Met, metastasis, motility and more [J]. Nat Rev Mol Cell Biol,2003,4 (12):915-925
[7]Rosario M, Birchmeier W. How to make tubes:signaling by the Met receptor tyrosine kinase [J]. Trends Cell Biol,2003,13(6):328-335
[8]Wislez M, Rabbe N, Marchal J, et al. Hepatocyte growth factor production by neutrophils infiltrating bronchioloalveolar subtype pulmonary adenocarcinoma:role in tumor progression and death [J].Cancer Res,2003,63(6):1405-1412
[9]Wang Yuping, Hao Zhiwei, Chu Tianjiao, et al.Expression of HGF and its receptor C-Met in breast cancer tissue [J]. Journal of Zhengzhou University,2005, 40(6):1133-1134. (In Chinese)
[10]Liu Ruijuan. Expression of Hepatocyte Growth Factor and its Receptor c-met in Non-small Cell Lung Carcinoma and Relationship between them [J] Practical Journal of Cancer,2006,21 (5):479-482. (In Chinese)
[11]Yu Shipeng, Guo Huan, Ban Bo, et al. Expression of thyroperoxidase mRNA, HGF/c-Met protein in human thyroid nodule [J].Shandong Chinese Medicine,2008, 48(34):15-17. (In Chinese)
[12]Kapos-Novak P, Lee JS, Gomez-Quimz L, et al. Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype [J]. J Clin Invest,2006,116(6):1582-1595
[13]Pongchairerk U, Guan JL, Leardkamolkam V. Focal adhesion kinase and Src phosphorylations in HGF-induced proliferation and invasion of human cholangiocarcinoma cell line, HuCCA-1 [J]. World J Gastroenterology,2005, 11(37):5845-5852
[14]Bauer TW, Somcio RJ, Fan F, et al.Regulatory role of c-Met in insulin-like growth factor-I receptor-mediated migration and invasion of human pancreatic carcinoma cells [J]. Mol Cancer Ther,2006,5(7):1676-1682
[15]Masuya D, Huang C, Liu D, et al. The tumour-stromal interaction between intratumoral c-Met and stromal hepatocyte growth factor associated with tumour growth and prognosis in non-small-cell lung cancer patients [J]. Br J Cancer,2004, 90(8):1555-1562
[16]Wasenius VM, Hemmer S, Karjalainen-Lindsberg ML, et al. MET receptor tyrosine kinase sequence alteration in differentiated thyroid carcinoma [J]. Am J Surg Pathol,2005,29(4):544-549
[17]Jagadeeswaran R, Ma PC, Seiwert TY, et al. Functional analysis of c-Met/ hepatocyte growth factor pathway in malignant pleural mesothelioma [J]. Cancer Res, 2006,66(1):352-361
[18]Qian CN, Guo X, Cao B, et al. Met protein expression level correlates with survival in patients with late-stage nasopharyngeal carcinoma [J].Cancer Res,2002, 62(1):589-596
[19]Dong Tong, Xin Xiaoyan, Ma Xiangdong. Hepatocyte growth factor and c-met's expression in ovarian tumor cell [J]. Clinical Cancer Research,2006,18(8):541-543 (In Chinese)
[20]Wang Yanfei, Pu Zhangjie, Yin Guangwen, et al. Progress on the relationship between HGF/c-Met system and the Head and Neck Cancer [J]. Practical Chinese Medicine,2008,3(3):135-137
[21]Zhang YW, Su Y, Volpert OV, et al. Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation [J]. Proc Natl Acad Sci USA,2003,100(22):12718-23
[22]Watson GA, Zhang X, Stang MT, et al. Inhibition of c-Met as a therapeutic strategy for esophageal adenocarcinoma. Neoplasia,2006, 11(8):949-955
[23]Wen J, Matsumoto K, Taniura N, et al. Inhibition of colon cancer growth and metastasis by NK4 gene repetitive delivery in mice [J]Biochem Biophys Res Commun,2007,358(1):117-123
[24]Hu Mingtai, Ha Xiaoqin, Gao Peng. The mechanism of Hepatocyte growth factor antagonist NK4 inhibiting the tumor [J]. Journal of Fourth Military Medical University,2008,29(1):86-88. (In Chinese)
[25]Matsumoto K, Nakamura T, Sakai K, et al. Hepatocyte growth factor and Met in tumor biology and therapeutic approach with NK4 [J].Proteomics,2008,8:3360-3370
[26]Raymond WW, Cruz AC, Caughey GH. Mast cell and neutrophil peptidases attack an activation segment in hepatocyte growth factor to generate NK4-like antagonists [J]. J Bilo Chem.2006,1281 (3):1489-1494
[27]Saga Y, Mizukami H, Suzuki M, et al. Expression of HGF/NK4 in ovarian cancer cells suppresses intraperitoneal dissemination and extends host survival [J]. Gene Ther,2001,8(19):1450-5
[28]Christensen JG, Burrow J, Salgia R. C-met as a target for human cancer and characterization of inhibitors for therapeutic intervention [J].Cancer Lett,2005, 225(1):1-26
[29]D avies G, Watkins G, Mason MD, et al. Targeting the HGF/SF receptor c-met using a hammerhead ribozyme transgene reduces in vitro invasion and migration in prostate cancer cells [J]. Prostate,2004,60(4):317-324
[30]Pan Weibing, Zhang Qinghan, Toshikazu Nakamura, et al. IntrAuction of exogenous NK4 gene into bladder transitional epithelial cells can reduce the HGF in tumor cells [J]. Chinese Journal of Experimental Surgery,2007,24(5):576-577. (In Chinese)
[31]Heideman DAM, Overmeer RM, Van Beusechem, et al. Inhibition of angiogenesis and HGF/c-Met-elicited malignant processes in human hepatocellular carcinoma cells using adenoviral vector mediated NK4 gene therapy [J]. Cancer Gene Ther,2005,12(12):954-962
[32]Buhles A, Collins SA, van Pijkerey JP, et al. Anti-metastatic effects of viral and non-viral mediated NK4 delivery to tumours [J]. Genet Vaccines and Ther, 2009,3(7):5